Saturday, March 21, 2020 - Live Webcast

Physicians’ Education Resource^®, LLC, understands the concerns surrounding the outbreak and spread of the coronavirus (COVID-19) currently affecting several countries. After monitoring the situation and information being shared by the CDC, and taking into account current travel restrictions, we have decided that the 5th Annual School of Gastrointestinal Oncology™ (SOGO^®) will be hosted as a live virtual webcast. Be assured that there is nothing more important to us than the safety of our participants which is why we are changing this to an online-only format.

Physicians’ Education Resource^®, LLC (PER^®), presents the 5th Annual School of Gastrointestinal Oncology™ (SOGO^®), a 1-day, multidisciplinary, educational conference dedicated to exploring emerging therapies and evolving standards of care in the management of patients with gastrointestinal (GI) tumors, with a focus on providing attendees with the tools to individualize patient care.

In GI cancer, solid tumors are often difficult to treat because of their heterogeneity. Optimized management of this disease requires a high level of multidisciplinary cooperation and multimodality treatment regimens, when appropriate. The rapid pace of emerging developments creates knowledge and competence gaps for physicians who treat patients with GI cancers.

Led by world-renowned experts John L. Marshall, MD, and Michael A. Choti, MD, MBA, FACS, this multi-track symposium, now in its fifth year, will provide attendees with the tools needed to personalize care for each one of their patients with GI cancer. The program will include various modules that feature general presentations on important concepts in the field, along with separate side tracks to provide workshops geared toward personalized learning in smaller and more intimate settings. With 3 tracks–medical oncology, surgical and radiation oncology, and case-based SOGO Seminars—the program is designed to match the learning interests of everyone who attends.

This year’s symposium will once again feature the dynamic and interactive Medical Crossfire^® format, where experts will engage in a rigorous debate to answer questions and reach consensus on ongoing paradigm shifts. The program will also feature case-based lectures by expert faculty that explore the latest data on prognostic and predictive biomarkers that impact clinical decision-making, and current and emerging treatment strategies. The focus will be on the practical application of this information to real-world, complex patient-care scenarios that exemplify key decision-making in diagnostic testing, upfront multidisciplinary planning, and management of treatment. PER^® will continue to use its proven educational modalities to provide for a highly interactive meeting that fosters discussion and exchange of ideas, best practices, and cross-team cooperation in the clinic. This will include case-based tumor boards, question-and-answer sessions, ARS polling, and networking opportunities.

“The evolution of treating patients who have GI cancers has really transformed over the past few years and will continue to do so moving forward. We know that personalizing disease in these tumors has to be done, and we need to involve the entire clinical team to do so. The expanded role of immune therapies, the importance of multidisciplinary care, and the role of precision medicine has further complicated the pathways of care. With all the advances that have been made in both treatment and care management, we have turned GI cancer into a chess game, and we need to make sure all the players and pieces are working together. This meeting will continue to educate the treatment team through multiple presentations and small group discussions and will truly be the most unique GI cancers meeting around.”

— John Marshall, MD
Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers
Georgetown University Medical Center
Washington, DC

• Build on learned information with insights from leading clinical experts on established and emerging treatment options in the management of GI cancer
• Implement protocols to support best practice treatment selection for your patients with GI cancer
• Amplify efforts to circumvent and manage treatment-associated adverse events for patients with GI cancer
• Network with your colleagues with different clinical expertise who manage patients with GI cancer

This activity is supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; Exelixis, Inc.; Genentech, Inc.; Incyte Corporation; Lilly; Merck & Co., Inc.; and Taiho Oncology, Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Physicians' Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 7.25 Contact Hours.

This educational program is directed toward oncologists and gastroenterologists whose primary practice focus is GI cancers, and who intend to reinforce their knowledge base and expand their expertise in GI diagnosis, risk stratification, personalization of care, and best practices for multidisciplinary communication. Participants will be primarily oncologists, gastroenterologists, or fellows-in-training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of GI cancers.

• Outline prognostic and predictive molecular markers that inform diagnosis and provide treatment guidance for patients with GI malignancies.
• Consider results from pivotal and practice changing clinical trials assessing new strategies for the treatment and management of patients with GI malignancies.
• Implement novel treatment strategies into clinical practice to improve the outcomes of patients with GI malignancies.
• Determine a comprehensive sequencing plan for GI malignancies’ management in the context of multidisciplinary collaboration between interventional radiology, surgical oncology, and medical oncology
• Assess methods to proactively plan for and mitigate the impact of treatment-related toxicities among patients with GI tumors